Background: Angiogenesis has been recognized an essential precondition for osteogenesis. Because reduction and disruption of the blood supply to tissue cause tissue hypoxia, pathological bone loss affected by hypoxia often can occur in various clinical conditions. The effects of propofol on the process of osteogenesis have received little direct attention. Therefore, we investigated the effect of propofol on the growth and function of osteoblasts under hypoxic condition. Methods: After propofol (3, 30, 300 μM) preconditioning for 2 hours, hFOB 1.19 human osteoblast cells were cultured under 1 % oxygen tension for 48 hours. Using real time PCR and western blot analysis, we analyzed the expression of, BMP-2, TGF-β1, type I collagen, osteocalcin, HIF-1s and Akt. Cell viability was also determined by MTT assay. Resul ts: Propofol preconditioning on hypoxic-cultured osteoblast promoted the expressions of BMP-2, TGF-β1, type I collagen and osteocalcin and induced hypoxia-mediated HIF-1 activation and the expression of Akt protein. Propofol with 300 μM significant decreased cell viability compared to control. Concl usi ons: Clinically relevant concentrations of propofol are not cytotoxic to hypoxic osteoblasts in vitro. Propofol preconditioning on hypoxic-cultured osteoblast stimulates proliferation and differentiation of osteoblast through induced expression of BMP-2, TGF-β1, type I collagen and osteocalcin. Propofol might promote angiogenesis and bone regeneration under hypoxic condition.
INTRODUCTION
Bone physiology is unusual in several respects. It appears an ability to regenerate and repair itself. A decrease of blood supply frequently occurs during impaired healing of fracture. This show that impaired angiogenic response is a major contributor to the pathology at the site of injury [1, 2] . The processes of endochondral bone formation and fracture repair are related with the invasion of blood vessels [3] . Some studies have shown that hypoxia increases osteoblast vascular endothelial growth factor (VEGF) and insulin-like growth factor-2 (IGF-2) expression [4, 5] .
In addition, hypoxia enhances bone morphogenetic protein-2 (BMP-2) expression in osteoblasts by hypoxia inducible transcription factor-1α (HIF-1α) [6] .
The hypoxia inducible transcription factor (HIF) is a heterodimer containing α and β subunits and it controls the oxygen-sensitive gene expression [7] . These target genes are related with various cellular processes including angiogenesis, energy metabolism, cell proliferation and survival, pH control, vasomotor control and matrix metabolism [8] .
Recent reports have demonstrated hypoxia decreases osteogenic differentiation [9] , cell proliferation [10, 11] and osteocalcin [12] and it is necessary for growth arrest and survival of chondrocytes [13] .
Propofol is an intravenous anesthetic drug widely used for general anesthesia and immediate postoperative or prolonged sedation in ICU patients. Propofol has also been shown to have protective effects against hypoxiainduced apoptosis in alveolar epithelial cell and inhibit HIF-1α-hypoxia responsive element axis [14] . Propofol increases BMP and decreases oxidative stress in sepsisinduced acute kidney injury [15] . Propofol was from Astrazeneca Ltd., Italy as the commercially available solution Diprivan (1%). Osteoblasts were exposed to various concentrations of propofol (3, 30, 300 μM) for 2 hours.
Hypoxia of cultured osteoblasts
The cells were cultured under 1% oxygen tension.
Cells were seeded on 96-well plate (1 x 10 4 cells) before exposure to hypoxia. Cells were gassed with 95% N2, and 5% CO 2 (Anaerobic System PROOX model 110;
BioSpherix, USA) and incubated at 34℃ within the chamber for 48h. 
Western blot assay
Cells were plated at a density of 1 x 105 cells in 6-well plates. Cells were washed twice with ice-cold PBS and centrifuged at 2,000 rpm for 10 min. Total cell proteins were lysed with a RIPA buffer [300 mM NaCl, 50 mM Tris-HCl (pH 7.6), 0.5% TritonX-100, 2 mM PMSF, 2 μg /ml aprotinin and 2 μg /ml leupeptin] and incubated at 4℃ for 1 h. 
Effect of propofol preconditioning on BMP-2, TGF-β1, type I collagen and osteocalcin
To examine the effect of propofol preconditioning on BMP-2, TGF-β1, type I collagen and osteocalcin in hFOB cells, cells were exposed to propofol at 3, 30 and 300 μM. Thereafter, the cells were cultured under 1% oxygen tension for 48 h.
The expression of BMP-2 mRNA was markedly increased throughout the experiment in all propofol treatment groups compared to the control group and peak the expression of BMP-2 mRNA was noted at treatment with 300 μM (Fig. 2A) . The expression of TGF-β1 mRNA was slightly increased in 30 and 300 μM groups compared to the control group. However, Treatment with 3 μM did not affect the expression of TGF-β1 mRNA (Fig. 2B ). The expression of Type I collagen was significantly increased in 30 and 300 μM groups compared to the control group. Unlike BMP-2 and TGF-β1, peak the expressions of type I collagen mRNA was noted at treatment with 30 μM (Fig. 2C) . The expression level of osteocalcin mRNA was higher in 30 and 300 μM groups than in the control group (Fig. 2D) . A similar effect of propofol was observed on the expression of TGF-β1 mRNA.
In Western blot analysis, similar to the results of PCR, propofol preconditioning is shown to increase the expressions of BMP-2, TGF-β1, type I collagen and osteocalcin protein (Fig. 3) .
These results suggest that propofol on hypoxic osteoblasts induces the expressions of BMP-2, TGF-β1, type I collagen and osteocalcin.
Effect of propofol preconditioning on HIF-1α, HIF-1β and Akt
In order to assess the effect of propofol precondi- (Fig. 3) .
These results suggest that propofol on hypoxic osteoblasts induces hypoxia-mediated HIF-1 activation and the expression of Akt protein.
DISCUSSION
The earlier studies have presented the effect of hypoxia on osteoblasts, but the effect of propofol on osteoblasts under hypoxia condition has not been documented until this study [4, 6] .
There are some studies on the contradictory effects of hypoxia on osteoblasts and osteoblastic cells. Park et al. [12] showed that hypoxia reduced the expression of The hypoxia-inducible factor-1 (HIF-1) pathway is the central regulator of adaptive responses to low oxygen availability and is required for normal skeletal development [27] . Under hypoxia, HIF-1α protein is markedly stabilized, translocates to the nucleus. The HIF-1 α and HIF-1β complex can then bind to hypoxia response elements (HREs) located in gene promoters to regulate transcription of vascular endothelial growth factor, erythropoietin, iNOS, and glycolytic enzymes that induce cellular adaptation to hypoxia [28, 29] . The expression of VEGF via the activation of the PI-3 kinase pathway has also been observed to be mediated by HIF-1 α [30, 31] .
Propofol is extensively used for the induction and maintenance of anesthesia during surgery and for ICU sedation [32] [33] [34] . It has recently focused greater attention due to its anti-apoptosis capability and antioxidant property [35] [36] [37] [38] . However, the direct effect of propofol on hypoxic osteoblasts has not been reported so far. Our preliminary experiment had showed that propofol pretreatment with 3 and 30 μM exhibits no cytotoxicity to hypoxic osteoblasts. But there were significant difference in cell viability between the control group and 300 μM group (Fig. 1) . Several previous studies presented similar results of propofol at therapeutic concentrations having no effect on macrophage and osteoblast viability. However, propofol at a high concentration (300 μM) increased lactate dehydrogenase release and led to an arrest of the cell cycle in the G1/S phase [39] .
The clinically relevant concentration of propofol was 3-11 μg/ml (approximately 17-62 μM /l) [40, 41] . Therefore, clinically relevant concentrations of propofol are not harmful to osteoblasts.
In this study, we showed that propofol preconditioning Because HIF-1 activation induce angiogenesis in hypoxic osteoblasts, this study suggests that propofol preconditioning accelerates bone regeneration. But, further studies about VEGF and several other genes will be required to ascertain effects of propofol preconditioning on angiogenesis and bone regeneration.
In conclusion, this study shows that clinically relevant concentrations of propofol are not cytotoxic to hypoxic osteoblasts in vitro and demonstrates that propofol preconditioning on hypoxic-cultured osteoblast stimulates proliferation and differentiation of osteoblast through induced expression of BMP-2, TGF-β1, type I collagen and osteocalcin. We assume propofol preconditioning promote angiogenesis and bone regeneration through HIF-1 activation.
